ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,179.20
0.60%
S&P 500
5,308.13
0.09%
US Dollar vs CAD
1.36249
0.12%
Bitcoin
71,247.72
-0.28%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Avenue Therapeutics Inc (ATXI)

  7. Avenue Therapeutics Inc (ATXI) News

ATXI

Avenue Therapeutics (ATXI)

Avenue Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATXI
DateTimeSourceHeadlineSymbolCompany
05/16/20247:30AMGlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
05/15/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
05/15/20247:30AMGlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
05/12/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
05/10/20243:53PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATXIAvenue Therapeutics Inc
05/10/20243:52PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXIAvenue Therapeutics Inc
04/29/20247:00AMGlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
04/24/20246:30AMGlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:ATXIAvenue Therapeutics Inc
03/25/20247:30AMGlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:ATXIAvenue Therapeutics Inc
03/18/20243:05PMGlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
03/15/20247:15AMGlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:ATXIAvenue Therapeutics Inc
03/11/20247:00AMGlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
03/08/20243:31PMEdgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
03/08/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
02/22/20247:30AMGlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:ATXIAvenue Therapeutics Inc
02/01/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
01/29/20247:00AMEdgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:ATXIAvenue Therapeutics Inc
01/24/20243:11PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXIAvenue Therapeutics Inc
01/17/20244:05PMEdgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
01/12/20245:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
01/11/20247:00AMGlobeNewswire Inc.Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceNASDAQ:ATXIAvenue Therapeutics Inc
01/08/20244:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
01/05/20248:15AMGlobeNewswire Inc.Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
01/04/20247:30AMGlobeNewswire Inc.Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolNASDAQ:ATXIAvenue Therapeutics Inc
01/02/20247:30AMGlobeNewswire Inc.Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
12/13/20233:03PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXIAvenue Therapeutics Inc
12/13/20233:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
12/01/20237:30AMGlobeNewswire Inc.Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
11/28/20233:05PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXIAvenue Therapeutics Inc
11/28/20233:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXI

Your Recent History

NASDAQ
FZIFGX
Limited Duration Fixed I...
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved